Indivior stock hits 52-week high at 16.36 USD

Indivior PLC (LON:INDV) stock reached a significant milestone by hitting a 52-week high of 16.36 USD, marking a robust performance for the $2 billion market cap pharmaceutical company. According to InvestingPro data, the company maintains a "GREAT" financial health score of 3.08 out of 5, with analysts setting price targets as high as $22. This achievement reflects a substantial 47.7% increase in the company’s stock price over the last 12 months, showcasing investor confidence and positive market sentiment. The pharmaceutical company, known for its addiction treatment products, has seen its stock price steadily climb, driven by strong financial results and strategic initiatives, including aggressive share buybacks by management. With annual revenues of $1.17 billion and an impressive gross profit margin of 81.6%, this 52-week high underscores Indivior’s resilience and growth potential in a competitive market landscape. For deeper insights into Indivior’s valuation and growth prospects, access the comprehensive Pro Research Report available exclusively on InvestingPro.

In other recent news, Indivior has undergone several noteworthy developments. Jefferies has assumed coverage of Indivior with a Buy rating, setting a price target of $20.00, citing reset expectations after a challenging 2024. In corporate leadership changes, Indivior announced the appointment of Patrick Barry as the new Chief Commercial Officer, effective June 2. Barry, who has over 30 years of experience in the pharmaceutical industry, will lead the company’s commercial growth strategy, focusing on its efforts to address opioid use disorder. Additionally, Tony Kingsley will join Indivior’s Board of Directors as an Independent (LON:IOG) Non-Executive Director, effective July 1, 2025. This appointment is supported by affiliates of Oaktree Capital Management. At the company’s Annual General Meeting, significant leadership changes were announced, including the departure of CEO Mark Crossley and the appointment of Joe Ciaffoni as the new CEO. Shareholders also approved amendments to the company’s articles of association, reflecting its transition from the London Stock Exchange (LON:LSEG) to the Nasdaq Stock Market as its primary listing. These developments indicate a period of strategic restructuring and leadership transformation for Indivior.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.